A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response

BACKGROUND: Antibodies blocking programmed cell death 1 (PD-1) have encouraging responses in patients with metastatic melanoma. Response to anti-PD-1 treatment requires pre-existing CD8+ T cells that are negatively regulated by PD-1-mediated adaptive immune resistance. Unfortunately, less than half...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wolf, Katrien, Kruse, Vibeke, Sundahl, Nora, van Gele, Mireille, Chevolet, Ines, Speeckaert, Reinhart, Brochez, Lieve, Ost, Piet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282822/
https://www.ncbi.nlm.nih.gov/pubmed/28137295
http://dx.doi.org/10.1186/s12967-017-1123-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282822/
https://www.ncbi.nlm.nih.gov/pubmed/28137295
http://dx.doi.org/10.1186/s12967-017-1123-x

Ejemplares similares